Plain-English translation of NCT05836896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This Phase I trial is testing whether MDC-CAR-BCMA001, a new type of treatment made from your own T cells (immune cells), can safely fight relapsed or refractory multiple myeloma and diffuse large B-cell lymphoma. The treatment is designed to teach your immune cells to recognize and attack cancer cells. The study is still in its early stages and will test different doses to find the safest and most effective level.
Many patients with advanced multiple myeloma or lymphoma run out of effective treatment options after standard therapies fail. This medication represents a new approach—using your own immune cells as a personalized weapon against cancer—and researchers need to first confirm it is safe before moving forward.
You likely qualify if…
You likely don't qualify if…
You will have your T cells collected from your blood in a process similar to dialysis (called apheresis). These cells are then sent to a laboratory where they are engineered to recognize cancer cells. While this happens, you may receive other treatments to prepare your body. Once the engineered cells are ready, you will receive them back as an intravenous infusion. The trial will test four different dose levels to find the safest and most effective dose, and you will be closely monitored for side effects and how well the treatment works.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
Germany